Moderna (MRNA) : progress report on cancer treatments

• Moderna (MRNA) today announced recent progress updates in its immune-oncology and rare disease programs and highlighted corporate objectives for 2019-2020. Included among this presentation, Moderna highlighted that based on previously reported clinical observations in two patients with advanced ovarian carcinoma in a Phase 1 study, it has submitted an IND amendment to the FDA and to the study's clinical research sites to commence a Phase 2 cohort of mRNA-2416 (OX40L) as a monotherapy in advanced ovarian carcinoma within its current Phase 1 study. An IND application has also been submitted to the FDA for mRNA-3704, Moderna's development candidate for methylmalonic acidemia. Moderna noted that it expects its cash, cash equivalents, and investments in marketable securities as of December 31, 2018 to be approx. $1.7 bln, compared to $902 mln as of December 31, 2017.